Takeda To Challenge U.S. Jury's $9 Billion Fine In Actos Drug Suit
This article was originally published in PharmAsia News
Takeda Pharmaceutical said it would appeal the order by a U.S. District Court that together with and Eli Lilly pay $9 billion in punitive damages for failure to disclose the adverse risks of its Actos (pioglitazone) diabetes drug.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.